MedPath

Short term effects of Nasal High Flow Therapy on autonomic nervous system function in patients with pulmonary arterial hypertension.

Not Applicable
Conditions
I27.0
Primary pulmonary hypertension
Registration Number
DRKS00013906
Lead Sponsor
Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
12
Inclusion Criteria

a. Age > 18 years (no age limit)
b. able to consent
c. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination for PAH -where there was no treatment with combination therapy in PAH patients then the reason must be documented-

Exclusion Criteria

- secondary (postcapillary) pulmonary hypertension (mean pulmonary arterial hypertension > 25 mmHg; PCWP >15 mmHg)
-COPD
- other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment
- severe neurological pre-existing conditions such as stroke, especially brainstem infarction
- intake of opioids
- severe psychiatric pre-existing conditions

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
High frequency component of heart rate variability [%], low frequency component of diastolic blood pressure variability [%]
Secondary Outcome Measures
NameTimeMethod
Heart rate [bpm], systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG], Borg Dyspnoea Scale [points]
© Copyright 2025. All Rights Reserved by MedPath